Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon

Summary.  Chronic delta hepatitis is the most severe form of chronic viral hepatitis for which interferon (IFN) is the only available treatment. In 39 patients (25 were treatment‐naïve, 14 had previously used IFN), efficacy of 1‐year treatment with IFN (9 MU, t.i.w.) or lamivudine (LAM; 100 mg, q.d.) alone was compared with IFN and LAM combination (2 months of LAM to be followed by combination treatment). IFN monotherapy was given only to treatment‐naïve patients. In both treatment‐naïve and previous IFN users, end of treatment virological and biochemical responses were similar with IFN–LAM combination and superior to LAM monotherapy (P < 0.05). Improvement in liver histology occurred more often with IFN ± LAM than with LAM alone (P < 0.05). In treatment‐naïve patients, combination treatment was not superior to IFN monotherapy. After treatment discontinuation, virological and biochemical response rates decreased in LAM and IFN combination and IFN monotherapy. On treatment virological response at month 6 of treatment predicted sustained virological response. The results of this study suggest that addition of LAM to IFN for the treatment of delta hepatitis is of no additional value and that both treatment modalities are superior to LAM monotherapy.

[1]  C. Yurdaydın,et al.  A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis , 2007, Journal of viral hepatitis.

[2]  A. Andriulli,et al.  Pegylated interferon alpha‐2b as monotherapy or in combination with ribavirin in chronic hepatitis delta , 2006, Hepatology.

[3]  D. Häussinger,et al.  Treatment of chronic hepatitis delta with pegylated interferon‐α2b , 2006 .

[4]  P. Marcellin,et al.  Efficacy of peginterferon alpha‐2b in chronic hepatitis delta: Relevance of quantitative RT‐PCR for follow‐up , 2006, Hepatology.

[5]  N. Sut,et al.  Efficacy of interferon α‐2b and lamivudine combination treatment in comparison to interferon α‐2b alone in chronic delta hepatitis: A randomized trial , 2006 .

[6]  M. Manns,et al.  Lamivudine therapy in chronic delta hepatitis: a multicentre randomized‐controlled pilot study , 2005, Alimentary pharmacology & therapeutics.

[7]  U. Akarca,et al.  Two-Year Interferon Therapy with Or without Ribavirin in Chronic Delta Hepatitis , 2005, Antiviral therapy.

[8]  K. Demır,et al.  Alpha Interferon and Ribavirin Combination Therapy of Chronic Hepatitis D , 2005, Antimicrobial Agents and Chemotherapy.

[9]  C. Yurdaydın,et al.  Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients , 2004, Archives of Virology.

[10]  M. Manns,et al.  Famciclovir treatment of chronic delta hepatitis. , 2002, Journal of hepatology.

[11]  R. D. de Man,et al.  Lamivudine–high dose interferon combination therapy for chronic hepatitis B patients co‐infected with the hepatitis D virus , 2000 .

[12]  P. Andreone,et al.  Lamivudine-Associated Remission of Chronic Hepatitis Delta , 2000, Annals of Internal Medicine.

[13]  E. Christensen,et al.  Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B , 2000, Gut.

[14]  J. Hoofnagle,et al.  Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. , 1999, Gastroenterology.

[15]  J. Hoofnagle,et al.  Lamivudine for chronic delta hepatitis , 1999, Hepatology.

[16]  R. Sidwell,et al.  Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine. , 1999, Antiviral research.

[17]  K. Shudo,et al.  Effect of Am-80, a Synthetic Derivative of Retinoid, on Experimental Arthritis in Mice , 1999, Pharmacology.

[18]  J. Casey,et al.  Genotype-Specific Complementation of Hepatitis Delta Virus RNA Replication by Hepatitis Delta Antigen , 1998, Journal of Virology.

[19]  R. Fontana,et al.  Combination therapy for chronic hepatitis B , 1997, Hepatology.

[20]  F. Callea,et al.  Long‐term interferon‐α treatment of children with chronic hepatitis delta: a multicentre study , 1996 .

[21]  W. Sheng,et al.  Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. , 1995, Gastroenterology.

[22]  J. Crespo,et al.  Correlation between hepatitis B viremia and the clinical and histological activity of chronic delta hepatitis , 1994, Medical Microbiology and Immunology.

[23]  P. van Eyken,et al.  Treatment of chronic hepatitis D with interferon alfa-2a. , 1994, The New England journal of medicine.

[24]  M. Brunetto,et al.  Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D , 1991, Hepatology.

[25]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[26]  D. Häussinger,et al.  Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[27]  S. Schalm.  Combination therapy for chronic hepatitis B. , 2003, Journal of Hepatology.

[28]  G. Plosker,et al.  Adefovir dipivoxil: a review of its use in chronic hepatitis B. , 2003, Drugs.

[29]  D. Faulds,et al.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B. , 1999, Drugs.

[30]  Combination therapy for hepatitis C. , 1998, TreatmentUpdate.

[31]  F. Callea,et al.  Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. , 1996, Journal of viral hepatitis.

[32]  F. Dubois,et al.  [Delta hepatitis]. , 1987, Presse medicale.